No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis

WESTLAKE VILLAGE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences

WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

WESTLAKE VILLAGE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today a… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

WESTLAKE VILLAGE, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock

WESTLAKE VILLAGE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological di… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological d… […]

No Picture
Nasdaq:ARQTUS03969K1088

Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

WESTLAKE VILLAGE, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. ((Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological … […]